Larimar Therapeutics — November 2026 Earnings Summary

Financial Performance:

• The press release contains no specific financial performance data, including revenue, earnings, profit margins, cash flow, debt, or deferred revenue figures.

Guidance and Future Outlook:

• Anticipates BLA submission acceptance in early 2027.
• Targets U.S. approval in mid-2027, contingent on FDA review.
• Plans to target a U.S. launch in Q3 2027, if approved.
• Aims to obtain and monetize a Rare Pediatric Disease Priority Review Voucher in mid-2027, if approved.
• The company is preparing for a potential U.S. launch to make nomlabofusp available to patients as quickly as possible following approval.

Business Segments and Product Lines:

• Completed a rolling Biologics License Application (BLA) submission to the FDA seeking accelerated approval for nomlabofusp for Friedreich's ataxia (FA).
• Nomlabofusp is an investigational protein replacement therapy designed to address frataxin deficiency by delivering human frataxin to mitochondria.
• The BLA seeks accelerated approval based on increases in skin frataxin (FXN) concentrations as a potential novel surrogate endpoint.
• Patients are currently enrolling in FORWARD-FA, a global confirmatory Phase 3 study evaluating daily subcutaneous use of nomlabofusp over 18 months in ambulatory participants ages 2 to 40.
• Approximately two-thirds of FORWARD-FA participants will be under the age of 21.
• Previously reported open-label data showed sustained increases in skin frataxin, with all evaluable participants at one year achieving levels within the range expected in asymptomatic heterozygous carriers.
• Directional improvements were observed across multiple clinical outcomes relative to a natural history reference population.
• Directional improvement of exploratory pharmacodynamic markers, including plasma lipids and peripheral tissue gene transcription, was observed compared to placebo-treated patients.
• The company plans to use its intracellular delivery platform to design other fusion proteins targeting additional rare diseases characterized by deficiencies in intracellular bioactive compounds.

Market and Competitive Landscape:

• Nomlabofusp is positioned as the first potential disease-modifying therapy to address the underlying cause of FA.
• There are currently no approved therapies for children under 16 years of age with FA.
• Nomlabofusp holds FDA Breakthrough Therapy Designation, Fast Track, Rare Pediatric Disease, and Orphan Drug designations for the treatment of FA in adults and children.
• The program was selected for the FDA's START pilot program, enabling more frequent interactions with the FDA.

Risks and Challenges:

• Completion of the BLA submission does not assure acceptance for filing or accelerated approval; the FDA may require additional information or studies.
• The FDA may not agree with the development strategy or determine that skin FXN is not an acceptable surrogate endpoint for accelerated approval.
• Patients with FA are expected to experience continued neurologic decline; while treatment has not shown worsening in most participants, the disease progression is a factor.
• Preliminary clinical trial results may differ from final results, and earlier data may not be predictive of later trial success.
• Risks include delays in patient recruitment, adverse events, and the ability to scale manufacturing processes.
• The company faces risks related to its ability to raise necessary capital, develop sales and marketing capabilities, and successfully commercialize approved products.

Management Commentary and Tone:

• Carole Ben-Maimon, MD, CEO, stated that completing the BLA submission is a major milestone and expressed confidence in the program grounded in sustained increases in skin frataxin and consistent directional improvements.
• Management noted that after treatment with nomlabofusp, they have not observed worsening in most participants but rather signs of improvement.
• The company is evaluating options to optimize its global commercialization strategy.
• Jen Farmer, MS, CEO of the Friedreich's Ataxia Research Alliance (FARA), highlighted the significance of the submission including data from adolescents ages 12 to 17.

Other Key Points:

• The BLA submission includes data from adolescents ages 12 to 17.
• The company is preparing for a potential U.S. launch with the goal of making nomlabofusp available to patients as quickly as possible following approval.
• The company is in the process of evaluating options to optimize its global commercialization strategy.
• The press release includes a detailed list of forward-looking statements and associated risks regarding regulatory approval, clinical trial outcomes, and commercialization.